Journal of Drugs in Dermatology皮肤病药物杂志
Journal of Drugs in Dermatology(英文缩写 J DRUGS DERMATOL),ISSN 1545-9616,eISSN 1545-9616,中文译名:皮肤病药物杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 1.608 | Q4 |
| 2022 | 1.500 | Q4 |
| 2023 | 1.500 | Q3 |
| 2024 | 1.800 | Q3 |
| 2025 | 2.200 | Q3 |
Journal of Drugs in Dermatology 最新收录文献
-
1. Topical Carboxytherapy as an Adjunct to Skin Recovery Post-CO2 Laser Fractional Resurfacing.
PMID:日期:2026-09-01Topical carboxytherapy, a transcutaneous carbon dioxide (CO2) delivery system, may support skin repair and regeneration, yet its role as an adjunct to fractional laser treatment remains underexplored. To investigate the effectiveness and safety of topical CO2 mask (CO2Lift® Carboxy Gel, Lumisque Skincare) in supporting skin recovery and improving clinical outcomes following fractional CO2 laser resurfacing. This 12-week randomized, placebo-controlled trial evaluated mild-to-moderate photoaging (n=6 females only). Participants received either topical carboxytherapy (n=4) or standard care (n=2). Assessments included VISIA-CR imaging, biophysical measurements, investigator ratings, and paired (baseline and 4-week) skin biopsies. Topical carboxytherapy accelerated recovery and was well-tolerated, with no major adverse events. VISIA-CR imaging showed accelerated erythema resolution, transepidermal water loss normalized more rapidly, and pH remained stable. Skin histology at week 4 revealed epidermal thickening and rete ridge formation with topical carboxytherapy vs placebo. Investigator ratings demonstrated significantly improved healing, global assessment, and global aesthetic improvement scale scores, with trends toward improvement in photodamage, rhytides, and pigmentation. Adjunctive topical carboxytherapy after fractional CO2 resurfacing accelerated healing, improved barrier recovery, and overall aesthetic outcomes. Larger studies are needed to confirm these findings.
-
2. Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin Treatment.
PMID:日期:2026-09-01Antiaging skin treatments are continuously in development to meet the needs of an aging population and counteract cosmetic effects of glucagon-like peptide-1 receptor agonists. Peptide Facial Refining Concentrate (ST26-PF-F1) serum contains multiple bioactive peptides within a penetrative delivery system. A clinical study of ST26-PF-F1 assessed its effects on skin health/appearance and tolerability/usability. This noncomparative 12-week study enrolled healthy females aged 45 years or older, Fitzpatrick phototypes I–VI, with evidence of skin aging. Participants applied ST26-PF-F1 twice daily. Efficacy (expert evaluation, instrumental measurements, confocal microscopy, and participant self-assessments) and tolerability/safety (dermatologist and participant reporting) were assessed at weeks 2, 4, 8, and 12. Statistically significant improvements from baseline were observed for expert evaluator global assessments of fine lines, skin elasticity and plumpness, and facial contour and facial sagging (all time points); and wrinkles and skin firmness (weeks 4, 8, and 12). Significant improvements were also observed in skin hydration and elasticity (all time points); wrinkle volume, depth, and skin texture (weeks 4, 8, and 12); and lifting effect and V-shape (week 12). Confocal microscopy showed statistically significant improvements in interkeratinocyte brightness, papilla morphology, and dermal collagen fibers at weeks 4 and 12 and surface uniformity and keratinocyte morphology at week 12. Participants reported skin improvements across multiple measures and overall product satisfaction. ST26-PF-F1 was well tolerated with no treatment-related stinging, itching, or discomforting sensations. Clinical, instrumental, and microscopy assessments of ST26-PF-F1 demonstrated wrinkle-modulating and filler-like effects, visibly more balanced-looking facial geometry, favorable tolerability, and user satisfaction.
-
3. A Novel Moisturizer Formulated With Micronized Centella asiatica and Mandelic Acid Improves Mature, Crepey Skin.
PMID:日期:2026-09-01Dermatoporosis is a condition of fragile, aging skin that manifests as altered pH, wrinkles, laxity, easy bruising, and hyperpigmentation. This study evaluated efficacy, safety, and subject perception after the use of a novel cream, GC (Galderma Laboratories, LP, Fort Worth, TX), on subjects with mature, aging skin. A 12-week multicenter, randomized, blinded, in-use study enrolled female and male subjects aged 40 to 60 years of all races, ethnicities, and Fitzpatrick skin types. Subjects were required to have a history of fragile skin and dry, crepey skin on the knees and thighs. GC cream was applied to knee and upper thigh skin twice daily. Assessments included clinical grading, digital photography, bioinstrumentation (skin texture, pH, and heatmap hydration), standard safety assessments, and satisfaction. Use of GC cream for 12 weeks resulted in significant improvements in skin crepiness, photodamage, and firmness, as well as decreased skin pH and early improvements in skin roughness and smoothness from baseline. Corneometer heatmapping documented improved skin hydration over baseline. No adverse events were reported; the GC cream was well tolerated, and subjects reported high satisfaction. Twice-daily application of the novel GC skin cream significantly improved the overall skin quality of mature, aging skin, including crepiness, photodamage, firmness, texture, pH, and hydration. GC cream was well tolerated with high subject satisfaction. These data are intended to help guide healthcare providers and patients in choosing an effective moisturizer that was specifically designed for patients with fragile, mature skin.
-
4. JAK/STAT Inhibitors Reduce Risk of New-Onset Keloids and Hypertrophic Scars: A Multi-Center Retrospective Cohort Study.
PMID:日期:2026-09-01Keloids and hypertrophic scars are fibroproliferative skin disorders characterized by excessive collagen deposition and high recurrence rates despite existing therapies. Emerging evidence implicates immune-mediated pathways, including Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling, in their pathogenesis. However, population-level data evaluating the association between JAK inhibitor exposure and keloid/hypertrophic scar risk are lacking. To evaluate whether initiation of JAK inhibitors is associated with a reduced risk of incident hypertrophic scar or keloid formation. Using a target trial emulation framework, we conducted a retrospective cohort study within the TriNetX US Collaborative Network. Adults without prior hypertrophic scar or keloid formation were classified as initiators of a JAK inhibitor or psoriasis comparators without JAK inhibitor exposure. Propensity score matching (1:1) balanced demographic characteristics, comorbidities, healthcare utilization, trauma history, and surgical exposure. The primary outcome was incident hypertrophic scar or keloid formation (ICD-10-CM L91.0) within 730 days. Risk ratios (RRs) and Cox proportional hazards models were used to estimate cumulative and time-to-event associations. After matching, 122,341 individuals were included in each group. Within two years, hypertrophic scar or keloid formation occurred in 0.14% of JAK inhibitor initiators versus 0.22% of comparators (RR 0.65, 95% CI 0.54-0.79; absolute risk difference -0.08%; P<0.001). JAK inhibitor initiation was also associated with a lower hazard of scar formation (HR 0.77, 95% CI 0.64-0.93). Initiation of JAK inhibitors was associated with a significantly reduced risk of incident hypertrophic scar or keloid formation. These findings support a potential role for JAK/STAT pathway modulation in keloid prevention and warrant prospective investigation.  .
-
5. Risk Factors Associated With Hyaluronic Acid Filler-Related Delayed Complications: A Literature Review and Expert Consensus.
PMID:日期:2026-09-01Delayed complications associated with hyaluronic acid (HA) fillers are a concern in aesthetic medicine. However, clinical strategies for mitigation remain inconsistent, and guidelines often make recommendations that may lack the support of robust evidence. To address this gap, a multidisciplinary expert safety council convened to develop evidence-based recommendations aimed at reducing the delayed complication risk of soft-tissue augmentation with fillers, noting which recommendations are uncertain due to lack of evidence. A structured advisory board meeting was held with 8 United States-based experts in aesthetic injectables. Discussions were informed by a comprehensive literature review, pre-meeting surveys, and real-time polling, with consensus statements refined following the meeting. The council reached full consensus on 8 key recommendations across 4 risk factor categories: patient history, product characteristics, procedural technique, and postprocedure care. A consistent theme across all categories was the lack of robust clinical evidence supporting many current guidelines, underscoring the need for more evidence-based recommendations. This expert consensus highlights the need for evidence-informed approaches to HA filler safety. While definitive data remain limited, the panel offers a practical framework for minimizing delayed complications and identifying priorities for future research.  .
-
6. Clascoterone Cream 1% is Safe and Effective for Papulopustular Rosacea: A Phase 2 Clinical Trial.
PMID:日期:2026-08-01Papulopustular rosacea (PPR) is a chronic inflammatory facial dermatosis with a need for well-tolerated and effective topical therapies. Clascoterone cream 1% is an androgen receptor inhibitor and a promising novel treatment for PPR. In this single-center, single-arm, phase 2 pilot study, adults with PPR applied clascoterone cream 1% twice daily to the face. The primary endpoint was biopsy-proven change in mean sebaceous gland number and diameter over 12 weeks. Secondary endpoints included Dermatology Life Quality Index (DLQI), patient-reported outcomes (PROs), and prevalence of adverse events. Twenty participants were enrolled, and 18 completed the study. Mean sebaceous gland count decreased significantly (4.94 ± 1.98 to 3.61 ± 2.33; P=0.012). Mean gland diameter also decreased, although not significantly (P=0.182). Mean DLQI scores significantly improved (7.5 ± 5.8 to 3.3 ± 5.6; P=0.029). PRO scores were favorable for papules/pustules (3.2 ± 1.1), facial redness (2.7 ± 1.0), general skin appearance (2.7 ± 1.1), and overall treatment satisfaction (3.1 ± 0.7). The treatment was well tolerated, with no serious adverse events. Mild, transient dryness (n=1) and eye irritation (n=1) resolved without intervention. Clascoterone cream 1% demonstrated favorable tolerability, safety, and efficacy in PPR, with significant improvements in sebaceous gland count and patient-centered outcomes. These findings support the therapeutic potential of clascoterone cream 1% for the treatment of PPR.  .
-
7. Molluscum Contagiosum in the Pediatric Population: Expert Consensus Guidance on Prevention and Treatment.
PMID:日期:2026-08-01Molluscum contagiosum (MC), caused by the molluscum contagiosum virus, is a common viral skin infection in children. MC may persist for months to years and can substantially impair the quality of life for affected children and their families through discomfort, pruritus, cosmetic concerns, social stigma, and household transmission. Newer US Food and Drug Administration (FDA)-approved therapies have demonstrated patient-acceptable clearance rates, providing clinicians with additional options to treat pediatric MC. The paper summarized literature on MC in childhood and provided evidence-based guidance to help clinicians manage pediatric MC. A panel of dermatologists developed a consensus paper to address the challenges of treating pediatric MC. The modified Delphi process comprised a two-pronged literature review, development of evidence-supported statements, physician review and modification, and a face-to-face panel meeting to discuss the systematic literature search results and draw on clinical experience and opinion to create six consensus statements, followed by voting. Consensus was achieved for 6 statements. Self-limiting, prolonged infection is common, particularly in children with impaired skin barrier conditions and immune deficiencies. Families may seek treatment to reduce patient discomfort from inflammatory symptoms, limit transmission, and reduce disease burden. Physicians should focus on patient and family quality of life through education and shared decision-making. Berdazimer gel 10.3% and cantharidin 0.7% are FDA-approved therapies that achieve meaningful lesion clearance (>50%) within 6 weeks to 3 months. The use of FDA-approved therapies with clinically meaningful clearance rates, combined with supportive management, provides an opportunity to improve outcomes and quality of life for children with MC.  .
-
8. Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex.
8. 克林霉素磷酸酯1.2%/阿达帕林0.15%/过氧化苯甲酰3.1%痤疮凝胶：按年龄和性别汇总分析PMID:日期:2026-08-01Acne pathophysiology and presentation may differ by patient age or sex. In clinical trials, clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel demonstrated efficacy and a positive safety profile in participants with moderate-to-severe acne. This post hoc analysis evaluated CAB efficacy/safety by age and sex. In one phase 2 and two phase 3 double-blind, randomized, 12-week trials, participants aged ≥9 years with moderate to severe acne applied once-daily CAB or vehicle. Efficacy endpoints included Evaluator's Global Severity Score ≥2-grade reduction from baseline and clear/almost clear (treatment success) and least squares mean changes from baseline in inflammatory/noninflammatory lesions. Treatment-emergent adverse events (TEAEs) were assessed. Pooled data were analyzed by subgroups: younger (9-24 years; n=274) and older females (≥25 years; n=121); younger (n=241) and older males (n=21). At week 12, in all subgroups, treatment success was greater with CAB (42.3%-54.1%) than with vehicle (15.0%-22.5%), and lesion reductions were ≥70% with CAB versus 44.5%–55.2% with vehicle. For all efficacy endpoints, CAB was superior to vehicle for younger participants and older females (P≤0.05, all). CAB TEAE rates were consistent with the overall population. In 3 clinical trials, CAB, the only fixed-dose, triple-combination topical for acne, demonstrated ≥70% lesion reductions, with good tolerability regardless of participants' sex or age.  .
-
9. Impact of Intermittent Fasting, Keto Diet vs Continuous Caloric Restriction on Psoriasis Severity: A Systematic Review and Meta-Analysis Protocol.
PMID:日期:2026-08-01Psoriasis is a chronic immune‑mediated inflammatory skin disease that is strongly associated with metabolic dysregulation and excess adiposity. Dietary strategies that reduce energy intake either by continuous daily caloric restriction (CCR) or time‑limited/periodic intake such as intermittent fasting (IF) or ketogenic diets (Keto) may improve psoriasis severity through weight loss, metabolic improvements, alterations in gut microbiota, and immune-metabolic effects. We aimed to compare the therapeutic effectiveness of IF, Keto, and CCR in reducing the severity of psoriasis. This study was designed as a systematic review and Meta Analysis. The clinical parameters such as psoriasis extent and outcome measures were evaluated at baseline at different follow up timeframes across studies. Outcome measures were assessed by changes in Psoriasis Area and Severity Index (PASI) scores, quality of life (dermatology life quality index [DLQI]), and metabolic scores. There was a significant PASI decrease in Keto and CCR cohorts (10-25.6 kg weight loss) compared with IF (0-2kg weight loss). No serious adverse effects were recorded in all interventions. The major limitations were study heterogeneity, lack of head-to-head comparisons, and follow up. CCR and Keto performed better than IF in managing psoriasis severity, suggesting personalized dietary routines as adjuncts to treatment.  .
-
10. Improved Sleep Quality in Psoriasis Patients Under Biologicals: A Prospective Observational Study.
PMID:日期:2026-08-01Sleep disorders are an underappreciated component of psoriasis-related morbidity. Biologic therapies targeting IL-17 and IL-23 may improve sleep quality by reducing systemic inflammation and improving signs and symptoms. To explore the association between moderate-to-severe psoriasis and sleep quality, as well to determine if IL-17 and IL-23 inhibitors may improve sleep disorders over 16 weeks. This prospective open, single center, observational cohort study enrolled patients with moderate-to-severe psoriasis treated with IL-17 or IL-23 inhibitors. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), pruritus, pain (measured using numeric scales for maximum and average intensity), and sleep quality (Pittsburgh Sleep Quality Index, PSQI) were evaluated at baseline, week 4, and week 16. Seventy patients exhibited moderate sleep impairment at baseline (mean PSQI 7.57). Pruritus and pain correlated significantly with poor sleep quality. Both IL-17 (n=30) and IL-23 inhibitors (n=40) significantly improved PASI, DLQI, pruritus, pain, and PSQI scores by week 16. IL-23 inhibitors demonstrated earlier PSQI improvement at week 4 (P=0.0057), while IL-17 inhibitors showed significant improvement only by week 16 in adjusted models (P=0.03). Regression analyses confirmed improvements in sleep remained significant after adjusting for confounders. Biologic therapy significantly improves sleep quality primarily through symptom control. IL-23 blockade might offer faster onset of sleep benefits, although both IL-17 and IL-23 therapies effectively improved sleep by week 16. Sleep quality may represent a meaningful therapeutic response measure in psoriasis management.  .